213 related articles for article (PubMed ID: 27730274)
1. [Progressive multifocal leukoencephalopathy].
Warnke C; Wattjes MP; Adams O; Hartung HP; Martin R; Weber T; Stangel M
Nervenarzt; 2016 Dec; 87(12):1300-1304. PubMed ID: 27730274
[TBL] [Abstract][Full Text] [Related]
2. Comparison of qPCR with ddPCR for the Quantification of JC Polyomavirus in CSF from Patients with Progressive Multifocal Leukoencephalopathy.
Ngouth N; Monaco MC; Walker L; Corey S; Ikpeama I; Fahle G; Cortese I; Das S; Jacobson S
Viruses; 2022 Jun; 14(6):. PubMed ID: 35746716
[TBL] [Abstract][Full Text] [Related]
3. Broadly neutralizing human monoclonal JC polyomavirus VP1-specific antibodies as candidate therapeutics for progressive multifocal leukoencephalopathy.
Jelcic I; Combaluzier B; Jelcic I; Faigle W; Senn L; Reinhart BJ; Ströh L; Nitsch RM; Stehle T; Sospedra M; Grimm J; Martin R
Sci Transl Med; 2015 Sep; 7(306):306ra150. PubMed ID: 26400911
[TBL] [Abstract][Full Text] [Related]
4. Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases.
Maas RP; Muller-Hansma AH; Esselink RA; Murk JL; Warnke C; Killestein J; Wattjes MP
J Neurol; 2016 Oct; 263(10):2004-21. PubMed ID: 27401179
[TBL] [Abstract][Full Text] [Related]
5. Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies.
Mentzer D; Prestel J; Adams O; Gold R; Hartung HP; Hengel H; Kieseier BC; Ludwig WD; Keller-Stanislawski B
J Neurol Neurosurg Psychiatry; 2012 Sep; 83(9):927-33. PubMed ID: 22807558
[TBL] [Abstract][Full Text] [Related]
6. Tau-protein concentrations are not elevated in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy.
Möhn N; Luo Y; Skripuletz T; Schwenkenbecher P; Zerr I; Lange P; Stangel M
Fluids Barriers CNS; 2019 Sep; 16(1):28. PubMed ID: 31484537
[TBL] [Abstract][Full Text] [Related]
7. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.
Tan CS; Koralnik IJ
Lancet Neurol; 2010 Apr; 9(4):425-37. PubMed ID: 20298966
[TBL] [Abstract][Full Text] [Related]
8. Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohort.
Wijburg MT; Warnke C; Barkhof F; Uitdehaag BMJ; Killestein J; Wattjes MP
J Neurol Neurosurg Psychiatry; 2019 Jan; 90(1):44-46. PubMed ID: 30100552
[TBL] [Abstract][Full Text] [Related]
9. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab.
Villar LM; Costa-Frossard L; Masterman T; Fernandez O; Montalban X; Casanova B; Izquierdo G; Coret F; Tumani H; Saiz A; Arroyo R; Fink K; Leyva L; Espejo C; Simó-Castelló M; García-Sánchez MI; Lauda F; Llufriú S; Álvarez-Lafuente R; Olascoaga J; Prada A; Oterino A; de Andrés C; Tintoré M; Ramió-Torrentà L; Rodríguez-Martín E; Picón C; Comabella M; Quintana E; Agüera E; Díaz S; Fernandez-Bolaños R; García-Merino JA; Landete L; Menéndez-González M; Navarro L; Pérez D; Sánchez-López F; Serrano-Castro PJ; Tuñón A; Espiño M; Muriel A; Bar-Or A; Álvarez-Cermeño JC
Ann Neurol; 2015 Mar; 77(3):447-57. PubMed ID: 25581547
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid analysis in 108 patients with progressive multifocal leukoencephalopathy.
Möhn N; Luo Y; Skripuletz T; Schwenkenbecher P; Ladwig A; Warnke C; Meuth SG; Wiendl H; Gross CC; Schröder C; Haghikia A; Stangel M
Fluids Barriers CNS; 2020 Oct; 17(1):65. PubMed ID: 33109245
[TBL] [Abstract][Full Text] [Related]
11. Progressive multifocal leukoencephalopathy: a review of the neuroimaging features and differential diagnosis.
Sahraian MA; Radue EW; Eshaghi A; Besliu S; Minagar A
Eur J Neurol; 2012 Aug; 19(8):1060-9. PubMed ID: 22136455
[TBL] [Abstract][Full Text] [Related]
12. Progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
Baldwin KJ; Hogg JP
Curr Opin Neurol; 2013 Jun; 26(3):318-23. PubMed ID: 23493158
[TBL] [Abstract][Full Text] [Related]
13. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.
Boster AL; Nicholas JA; Topalli I; Kisanuki YY; Pei W; Morgan-Followell B; Kirsch CF; Racke MK; Pitt D
JAMA Neurol; 2013 Mar; 70(3):398-402. PubMed ID: 23338729
[TBL] [Abstract][Full Text] [Related]
14. The human JC polyomavirus (JCPyV): virological background and clinical implications.
Hirsch HH; Kardas P; Kranz D; Leboeuf C
APMIS; 2013 Aug; 121(8):685-727. PubMed ID: 23781977
[TBL] [Abstract][Full Text] [Related]
15. Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: epitope definition and implications in risk stratification of patients under natalizumab therapy.
Diotti RA; Mancini N; Clementi N; Sautto G; Moreno GJ; Criscuolo E; Cappelletti F; Man P; Forest E; Remy L; Giannecchini S; Clementi M; Burioni R
Antiviral Res; 2014 Aug; 108():94-103. PubMed ID: 24909571
[TBL] [Abstract][Full Text] [Related]
16. Adoptive Transfer of JC Virus-Specific T Lymphocytes for the Treatment of Progressive Multifocal Leukoencephalopathy.
Berzero G; Basso S; Stoppini L; Palermo A; Pichiecchio A; Paoletti M; Lucev F; Gerevini S; Rossi A; Vegezzi E; Diamanti L; Bini P; Gastaldi M; Delbue S; Perotti C; Seminari E; Faraci M; Luppi M; Baldanti F; Zecca M; Marchioni E; Comoli P
Ann Neurol; 2021 Apr; 89(4):769-779. PubMed ID: 33459417
[TBL] [Abstract][Full Text] [Related]
17. Prevention and therapy of JC polyomavirus-mediated progressive multifocal leukoencephalopathy - a realistic possibility?
Jelcic I; Combaluzier B; Jelcic I; Sospedra M; Grimm J; Martin R
Swiss Med Wkly; 2017; 147():w14520. PubMed ID: 29120025
[TBL] [Abstract][Full Text] [Related]
18. Infrequent detection of KI, WU and MC polyomaviruses in immunosuppressed individuals with or without progressive multifocal leukoencephalopathy.
Dang X; Bialasiewicz S; Nissen MD; Sloots TP; Koralnik IJ; Tan CS
PLoS One; 2011 Mar; 6(3):e16736. PubMed ID: 21436884
[TBL] [Abstract][Full Text] [Related]
19. Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?
Cutter GR; Stüve O
Mult Scler; 2014 Sep; 20(10):1304-5. PubMed ID: 24812045
[TBL] [Abstract][Full Text] [Related]
20. Review of progressive multifocal leukoencephalopathy and natalizumab.
Aksamit AJ
Neurologist; 2006 Nov; 12(6):293-8. PubMed ID: 17122725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
